The immunogenicity of anti-TNF therapy in immune-mediated inflammatory diseases: a systematic review of the literature with a meta-analysis

• Published in: Annals of the rheumatic diseases Vol. 72; no. 12; pp. 1947 - 1955
• Main Authors: Garcês, Sandra, Demengeot, Jocelyne, Benito-Garcia, Elizabeth
• Format: Journal Article
• Language: English
• Published: United States BMJ Publishing Group Ltd and European League Against Rheumatism 01.12.2013; Elsevier Limited
• Subjects: Adalimumab; Anti-Inflammatory Agents, Non-Steroidal - immunology; Anti-Inflammatory Agents, Non-Steroidal - therapeutic use; Anti-TNF; Antibodies, Monoclonal - immunology; Antibodies, Monoclonal - therapeutic use; Antibodies, Monoclonal, Humanized - immunology; Antibodies, Monoclonal, Humanized - therapeutic use; Antibody Formation - drug effects; Antirheumatic Agents - immunology; Antirheumatic Agents - therapeutic use; Arthritis - drug therapy; Arthritis - immunology; Autoimmune Diseases; Autoimmune Diseases - drug therapy; Autoimmune Diseases - immunology; Biological products; Clinical medicine; Clinical trials; Crohn's disease; Drug dosages; Evidence-Based Medicine - methods; Humans; Immunoglobulins; Immunosuppressive Agents - pharmacology; Immunotherapy; Inflammatory bowel disease; Inflammatory Bowel Diseases - drug therapy; Inflammatory Bowel Diseases - immunology; Infliximab; Literature reviews; Measurement techniques; Meta-analysis; Methotrexate; Methotrexate - pharmacology; Patients; Studies; Tumor Necrosis Factor-alpha - antagonists & inhibitors; Tumor necrosis factor-TNF; Anti-TNF; Methotrexate; Autoimmune Diseases

Background Immunogenicity of aTNFs is one of the mechanisms behind treatment failure. Objective To assess the effect of anti-drug antibodies (ADA) on drug response to infliximab, adalimumab and etanercept, and the effect of immunosuppression on ADA detection, in patients with Rheumatoid Arthritis, S...